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Prostate adenocarcinoma is the most common newly diagnosed cancer in males. Pulmonary and pleural
metastasis are not uncommon on autopsy, but malignant effusions are not common clinical ﬁndings.
There are no current recommendations to guide prostate speciﬁc antigen level assessment in pleural
ﬂuid.
A 73 yo w/prostate cancer presented with complaints of subacute worsening of exertional dyspnea. He
underwent a CT of the chest which excluded pulmonary emboli but did show moderate to large bilateral
pleural effusions.
The patient had a thoracentesis performed which conﬁrmed an exudative effusion with atypical cells
and elevated PSA levels. Metastatic visceral & parietal foci of prostate adenocarcinoma were found on
medical pleuroscopy. The patient was symptomatically treated with bilateral tunneled chest tube
catheters for intermittent drainage.
Pulmonary metastasis secondary to prostate cancer is commonly found on autopsy, with pulmonary
metastasis in 46% of patients and pleural metastasis in 21% of patients. Pleural effusions are not common,
in one series, only 6/620 (1%) were found to have pleural masses/nodules or effusions. Diagnosis of
pleural effusion secondary to metastatic prostate cancer can be achieved by direct cytology evaluation
and/or PSA level elevation in the ﬂuid. While speciﬁc, the sensitivity is not high enough to rule out
disease if negative. Elevated pleural ﬂuid PSA levels may aid in the diagnosis; however, there are no
current recommendations as to what level may be considered diagnostic. Further studies are needed to
deﬁne the sensitivity and speciﬁcity of PSA in pleural ﬂuid.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
A patient with metastatic prostate adenocarcinoma presented
with subacute dyspnea and signiﬁcant bilateral pleural effusions.
The effusionwas exudativewith atypical cells and elevated prostate
speciﬁc antigen (PSA) levels. Metastatic visceral & parietal foci of
prostate adenocarcinoma were found on medical pleuroscopy. The
patient was symptomatically treated with tunneled chest tube
catheters for drainage.Case report
A 73-year-old former smoker with medical castration-resistant
metastatic prostate cancer, currently on Abiraterone, presented
with complaints of subacute worsening of exertional dyspnea. He: þ1 513 558 4858.
night).
Ltd. This is an open access article uunderwent a CT of the chest with contrast which excluded pul-
monary emboli but did show moderate to large bilateral pleural
effusions.
A left sided thoracentesis revealed an exudative effusion with a
total protein of 28 g/L (2.8 g/dL) and a serum to pleural ﬂuid protein
ratio of 0.57. The LDH, cholesterol, and glucose were within tran-
sudative range. Cell count showed 460 nucleated cells w/atypical
cells that stained weakly positive for CEA. The PSA level in the
pleural ﬂuid was 1619 mg/L (ng/mL), the serum level was 2540 mg/
L (ng/mL).
Removal of two liters of pleural ﬂuid resulted in symptomatic
improvement. The patient returned seven days later for recurrent
dyspnea. A right sided thoracentesis was performed which resulted
in improvement of symptoms. The pleural ﬂuid PSA level was
1936 mg/L (ng/mL).
Given the rapid reoccurrence with symptomatic improvement
after drainage, evaluation for pleurodesis was recommended. A
medical pleuroscopy was performed which showed severely
inﬂamed, nodular parietal and visceral pleurae with lungnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1. Biopsy of pleural metastatic foci staining positive for prostate speciﬁc antigen
staining [orange].
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prostate origin. Bilateral tunneled drainage catheters were placed
for intermittent drainage given the lung entrapment (see Fig. 1).
Discussion
Prostate adenocarcinoma is the most common newly diagnosed
cancer inmales [1,2] and is the third leading cause of death inmales
following lung& colon cancer [3]. At the time of presentation, many
patients will have distant metastases, most commonly involving
regional lymph nodes (pelvic& abdominal retroperitoneal)& bone.
Pulmonarymetastasis secondary to prostate cancer is discovered in
less than 1% of patients during their lifetime [4]. The prevalence of
pulmonary metastatic disease is signiﬁcantly higher on autopsy,
with pulmonary metastasis in 46% of patients and pleural metas-
tasis in 21% of patients [5]. A retrospective study of 508 patients
with prostate cancer identiﬁed pulmonary involvement in only
four cases, with no identiﬁable cases of pleural involvement or ef-
fusions [6]. Vinjamoori et al. determined the most frequent site of
atypical metastasis, deﬁned as any involvement outside the
abdomen and pelvis, was the lung and pleura, occurring in 5% of
total cases and in 40% of atypical metastatic cases. Of those cases
with pulmonary involvement, only 1% were found to have pleural
involvement or effusions. Interestingly, all of the patients with
pleural metastasis had concurrent osseous metastases which pre-
dated the pleural involvement on imaging [7]. In a retrospective
radiological evaluation of 198 patients with advanced prostate
cancer performed by Apple et al., pleural effusions were found in
22% cases, 13.6% of these were conﬁrmed to be malignant [8].
Diagnosis of pleural effusion secondary to metastatic prostate
cancer can be achieved by cytologic examination with immuno-
staining for PSA.While speciﬁc, the sensitivity is not high enough to
rule out disease if negative [9]. Cascinu et al. evaluated tumor
markers in malignant pleural effusions and found PSA elevated inall effusions caused by prostate adenocarcinoma [10]. There has
been at least one transudative pleural effusion caused by prostate
adenocarcinoma diagnosed by elevated pleural PSA levels [11].
There is also a case report of prostate cancer diagnosed via malig-
nant effusion without known disease elsewhere [12].
In summary, malignant effusions from prostate adenocarcinoma
remain a rare clinical ﬁnding. Conventional cytology may miss the
diagnosis. Elevated pleural ﬂuid PSA levels can aid in the diagnosis.
There are no current recommendations as to what level may be
considered diagnostic. Our case and other reports support the
ﬁnding that pleural ﬂuid PSA levels are markedly elevated in ma-
lignant effusions secondary to prostate cancer. Further studies are
needed to deﬁne the sensitivity and speciﬁcity of PSA in pleural
ﬂuid at a certain diagnostic threshold.Acknowledgments
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